Variant interpretation: how to accelerate the adoption of genomic diagnosis in dementia

2019년 3월 7일

Is genetic screening better at prediction of disease than the current traditional phenotypic methods? Do we have enough expertise to move genetic diagnosis into the clinic? Is direct-to-consumer genetics dangerous? Find out what leading dementia researchers think about the trends in the field and what are their recommendations for the future. Panelists in the session: -Dr. Jonathan Rohrer, University College London -Prof. Julie Williams, UKDRI, University of Cardiff -Prof. Anne Bassett, University of Toronto Session moderated by: Prof. John Hardy, UKDRI, University College London For other videos and dementia research-related resources, visit http://ion.illumina.com/genetics-of-dementia-resource-library-yt For Research Use Only. Not for use in diagnostic procedures QB #6255 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

다음을 통해 기사 공유하기: